secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2022-03-21T23:59:59+00:00
Accession:  0001493152-22-007328
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix reports positive Phase 1b top-line data for PUR1800 in stable COPD
----------------------------------------------------------------------------

- PUR1800 well-tolerated with no safety signals in 18-subject Phase 1b study.
- Preliminary PK shows low and consistent systemic exposure via oral inhalation.
- Company expects to advance PUR1800 to Phase 2 studies for AECOPD.
- Results to be submitted at a medical conference later in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222007328/0001493152-22-007328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222007328/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-007328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer